UBS Raises Moderna Price Target to $45, Cites Upcoming Pipeline Readouts

Moderna, Inc. (NASDAQ: MRNA) drew renewed analyst attention after UBS lifted its price target while keeping its Neutral stance, pointing to a cluster of expected pipeline updates that could swing sentiment if trial data come in stronger than investors currently assume. The move was highlighted in a Yahoo Finance post dated June 2, 2026, summarizing coverage that traced back to a UBS note reported by TheFly on May 4, 2026.

In that UBS update, the firm raised its price target on Moderna to $45 from $36 and maintained a Neutral rating. Price targets are analyst estimates of what a stock could be worth based on their view of future performance, while a Neutral rating generally indicates the analyst does not expect meaningful upside or downside relative to its base-case assumptions.

UBS tied the outlook to what it described as a series of pipeline catalysts, meaning discrete moments when clinical results or other program milestones could change the perceived value of the company’s pipeline. In a separate recap of UBS commentary published by, the firm emphasized a specific clinical event for the company’s INT adjuvant melanoma program: a Phase III interim analysis. A Phase III study is the later-stage clinical trial designed to confirm efficacy and safety, and an interim analysis is a planned checkpoint where results are reviewed before the study concludes.

According to the report, Moderna guided the interim analysis for 2026, with UBS estimating a potential timeframe around October or November. UBS assigned a probability of success above 50% for that interim look and suggested the stock could move 25% to 50% higher if the interim analysis meets its endpoint. The report also laid out a risk scenario in which the study does not stop at the interim analysis, potentially requiring investors to wait for final readouts if the separation of survival curves takes longer than expected.

The catalyst focus lands against Moderna’s broader development strategy centered on messenger RNA, or mRNA, medicines. mRNA platforms use instructions delivered into the body to prompt cells to produce target proteins, which can then train the immune system or address disease mechanisms. Moderna’s investor materials describe development programs spanning respiratory vaccines and therapeutics, including COVID-19 and influenza programs, as well as therapeutic candidates such as Intismeran autogene (mRNA-4157) and a checkpoint adaptive immune modulation therapy program (mRNA-4359).

Still, the analyst-driven coverage does not provide a full catalogue of which additional pipeline items UBS expects investors to re-rate next, beyond the general reference to multiple catalysts and the emphasis on the INT melanoma interim milestone. UBS also did not disclose, in the publicly available summaries, how it quantifies the financial impact of each individual trial event on future revenue, margins, or probability-weighted valuation. That leaves investors to translate “pipeline updates” into expected commercial outcomes and timelines based on their own models.

What to watch next is the timing and substance of clinical data in 2026, particularly any announcements that clarify whether the INT adjuvant melanoma interim analysis proceeds on schedule and whether it reaches meaningful efficacy targets. For Moderna, trial endpoints and interim stopping rules can directly affect perceived de-risking of programs, which is often why analysts tie valuation shifts to specific calendar windows rather than to broader long-term narratives.